This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content is only relevant to HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

Profile

Efficacy

Praluent® is associated with a reduction in major adverse cardiovascular events in the ODYSSEY OUTCOMES CVOT2

Flexibility of dose

Praluent® offers different dosing options to suit your patient1

Safety Profile

Praluent® offers a favourable long-term safety and tolerability profile demonstrated over 5 years in ODYSSEY OUTCOMES1,2

1/3

Efficacy

Praluent® is associated with a reduction in major adverse cardiovascular events in the ODYSSEY OUTCOMES CVOT2

Flexibility of dose

Praluent® offers different dosing options to suit your patient1

Safety Profile

Praluent® offers a favourable long-term safety and tolerability profile demonstrated over 5 years in ODYSSEY OUTCOMES1,2

References

1. Praluent Summary of Product Characteristics. Available at https://www.medicines.org.uk/emc/product/8093/smpc. Accessed October 2023

2. Schwartz G, et al. N Engl J Med 2018;379:2097–2107.

Indication, Mechanism of Action and Administration

Indication

Mechanism of Action

Administration

1/3

Indication

Mechanism of Action

Administration

Expert Hub Videos

Resources include links to videos from Dr Derek Connolly (Consultant Cardiologist, Birmingham UK) discussing topics such as recommended guidance, current clinical trials and peer-2-peer sharing of clinical practice.

Lipid Optimization in ACS patients

In the following video Dr Connolly discusses the evidence for LDL-C causality, the difference between high risk and very high risk patients and the reasons why a post-ACS patient should be screened for lipid optimisation.

The Intensive Lipid-Lowering Approach

In the following video Dr Connolly explains the intensive lipid-lowering therapy approach in high and very high risk ASCVD patients and why this is needed.

Implementing the Intensive Lipid-Lowering Approach

In the following video Dr Connolly discusses implementing the intensive lipid-lowering therapy approach in clinical practice.

Get in touch with the Dyslipidaemia Team

MAT-XU-2204604 (v4.0) Date of Preparation: October 2023